Pfizer’s Q3 2025 Earnings: What to Expect

Core Insights - Pfizer Inc. has a market capitalization of $139.4 billion and is recognized for its development of medicines and vaccines in oncology, immunology, and infectious diseases [1] - The company is expected to report a fiscal Q3 2025 adjusted EPS of $0.68, reflecting a 35.9% decrease from $1.06 in the same quarter last year [2] - For fiscal 2025, analysts project an adjusted EPS of $3.07, down 1.3% from $3.11 in fiscal 2024, with a forecasted growth to $3.15 in fiscal 2026 [3] Stock Performance - Pfizer's shares have declined by 8.2% over the past 52 weeks, underperforming the S&P 500 Index, which rose by 11.9%, and the Health Care Select Sector SPDR Fund, which decreased by 7.1% [4] - On October 6, Pfizer's shares increased by 7.2% following a significant agreement with the U.S. government aimed at reducing prescription drug prices, which includes various pricing strategies and a $70 billion investment in U.S. research and manufacturing [5] Analyst Ratings - The consensus rating for Pfizer stock is moderately optimistic, categorized as a "Moderate Buy" overall, with 24 analysts providing coverage [6] - Among these analysts, six recommend a "Strong Buy," one has a "Moderate Buy," 16 suggest a "Hold," and one advises a "Strong Sell," with a mean price target of $28.48 indicating a potential upside of 16.8% from current levels [6]